This Phase trial is recruiting patients with relapsed or refractory MM using the drug, Tazemetostat EPZ, which was developed by Epizyme. 이 연구는 두 부분으로 나뉘어 진행됩니다. Part involves a pharmacokinetics study of MM patients, without regard to BAP status, following a single drug dose.